december 7, 2023

Ectin to attend Go West with new preclinical data on MFA-370 treatment for metastatic cancer tumors

Ectin Research CEO Anna Anna Sjöblom-Hallen will attend the Go West investor event in Gothenburg, February 7-8, 2024, with the company’s new preclinical data on MFA-370, its repurposed combination therapy for the treatment of metastatic cancer tumours.

Ectin recently announced new preclinical results further strengthening its case as a potential treatment for metastatic urothelial bladder cancer (mUBC) and demonstrating promising results for triple negative breast cancer (TNBC) and the orphan disease uveal melanoma (UM).

MFA-370 is a repurposed combination therapy for cancer tumours planned to be taken as a simple oral tablet with few if any side effects. In previous preclinical studies it has achieved positive antiproliferative results demonstrating how it has significantly inhibited the growth of breast, colorectal and prostate tumour cells.

CEO Anna Anna Sjöblom-Hallen: “I look forward to attending Go West with our new preclinical results. We are excited and determined to continue to drive our research projects forward. We are convinced that MFA-370 could offer a new treatment option and enhanced quality of life for cancer patients”.

The Go West Nordic Venture Capital Forum is one of the Nordic’s premier venture capital forums for investors, startups and scaleups.

Register for the event here.

Contact Ectin Research here.